Kjetil Boye

21PUBLICATIONS
178CO-AUTHORS
Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markersSolid tumoursCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (21)

|Jun 11, 2025
Real-world data on immune checkpoint inhibitors in advanced sarcomas across multiple European institutions.

Stefania Kokkali, Ana Dolcan, Kjetil Boye

|May 23, 2025
Updated Overall Survival and Long-Term Safety With Ripretinib Versus Sunitinib in Patients With GI Stromal Tumor: Final Overall Survival Analysis From INTRIGUE.

Michael C Heinrich, Jean-Yves Blay, Hans Gelderblom

|Mar 26, 2025
Imatinib alternating with regorafenib compared to imatinib alone for the first-line treatment of advanced gastrointestinal stromal tumor: The AGITG ALT-GIST intergroup randomized phase II trial.

Desmond Yip, John Zalcberg, Jean-Yves Blay

|Jun 13, 2024
Biological Sample Collection to Advance Research and Treatment: A Fight Osteosarcoma Through European Research and Euro Ewing Consortium Statement.

Darrell Green, Roelof van Ewijk, Elisa Tirtei

|Jun 11, 2024
Survival of patients with ruptured gastrointestinal stromal tumour treated with adjuvant imatinib in a randomised trial.

Heikki Joensuu, Annette Reichardt, Mikael Eriksson

|Apr 01, 2024
Systematic analysis of RNA-binding proteins identifies targetable therapeutic vulnerabilities in osteosarcoma.

Yang Zhou, Partho Sarothi Ray, Jianguo Zhu

Pageof 4

Frequent Collaborators

4 joint publications

Robin L Jones

3 joint publications

Toto Hølmebakk

3 joint publications

Jean-Yves Blay

3 joint publications

Hans Gelderblom